Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

1. ONS-5010 showed non-inferiority to NVS's Lucentis in key trial. 2. BCVA improvements for ONS-5010 were lower than for Lucentis at week 12. 3. Outlook plans to resubmit BLA for ONS-5010 in Q1 2025. 4. ONS-5010 is approved in EU and UK; European launch planned for 2025. 5. OTLK stock dropped 9.78%, indicating market skepticism.